TAT-Gap19 TFA 是一种 Cx 模拟肽，是一种特定的 connexin43 半通道 (Cx43 HC) 抑制剂。TAT-Gap19 TFA 不抑制相应的 Cx43 GJC。TAT-Gap19 TFA 可以透过血脑屏障，减轻小鼠的肝纤维化。
货号:ajcx33364
CAS:N/A
分子式:C121H213F3N46O28
分子量：2817.27
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice[1][2][3].

A single injection of TAT-Gap19 TFA (i.v. via the tail vein; 55 mg/kg) produces significant immune signal in the brain 24 h later in 4 months old C57Bl6 male mice[1]. TAT-Gap19 TFA (1 mg/kg/day; an osmotic pump implanted in the peritoneal cavity; Two weeks) shows significantly decreased collagen deposition, as well as lowed amounts of α-SMA-positive cells area in mice subjected to treatment with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks[2].

[1]. VerÓnica Abudara, et al. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014 Oct 21;8:306.
[2]. Sara Crespo Yanguas, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3):817.
[3]. Laura Walrave, et al. Inhibition of astroglial connexin43 hemichannels with TAT-Gap19 exerts anticonvulsant effects in rodents. Glia. 2018 Aug;66(8):1788-1804.